IADR Abstract Archives
Osteogain – A New Formulation of Enamel Matrix Derivative for Bone Grafting Materials
Objectives: The clinical use of an enamel matrix derivative (EMD, Emdogain-gel) has been shown to significantly enhance the clinical outcomes following regenerative periodontal surgery. In certain clinical situations however, the use of Emdogain alone may not be sufficient to prevent a flap collapse or provide sufficient stability to form a blood clot. Therefore, the clinical combination of Emdogain with various bone grafting materials has been investigated with the aim of improving periodontal regeneration. While the combination of some bone grafting materials with Emdogain seems to favour periodontal regeneration, others seem to show no additional benefit when compared to either bone grafting material alone or to Emdogain alone. Therefore, the aim of the study was to investigate a plausible understanding for the observed clinical variations and thereafter develop a novel carrier system for EMD specifically designed for bone graft mixing.
Methods: Emdogain-gel was compared to a liquid formuation of EMD for the adsorption of amelogenin proteins. Thereafter a novel carrier system for EMD was developed specifically for bone graft mixing (termed Osteogain). The new carrier system for EMD was then compared to Emdogain-gel for its effects on cell behavior, over a gene super-array on osteogenesis, as well as in a critical-sized rat femur defect for bone healing at 2,4 and 8 weeks.
Results: The commercially available Emdogain gel adsorbed less amelogenin protein when compared to a liquid formulation of EMD and the results were consistent using 3 different bone grafts. Following optimization of the carrier system, Osteogain demonstrated comparable effects to Emdogain on osteoblast and PDL cell proliferation and differentiation. PDL cells seeded on bone grafts pre-coated with Osteogain demonstrated significant increases in genes transcribed during bone mineralization, bone metabolism, cell growth and differentiation, extracellular matrix molecules, transcription factors and cell adhesion molecules. Lastly, we demonstrate that the application of Osteogain mixing with bone grafting significantly increases new bone formation in a rat femur defect model.
Conclusions: The development of a new carrier system for EMD specifically for bone graft mixing demonstrates more ideal physical-chemical properties suitable for future clinical use.
Methods: Emdogain-gel was compared to a liquid formuation of EMD for the adsorption of amelogenin proteins. Thereafter a novel carrier system for EMD was developed specifically for bone graft mixing (termed Osteogain). The new carrier system for EMD was then compared to Emdogain-gel for its effects on cell behavior, over a gene super-array on osteogenesis, as well as in a critical-sized rat femur defect for bone healing at 2,4 and 8 weeks.
Results: The commercially available Emdogain gel adsorbed less amelogenin protein when compared to a liquid formulation of EMD and the results were consistent using 3 different bone grafts. Following optimization of the carrier system, Osteogain demonstrated comparable effects to Emdogain on osteoblast and PDL cell proliferation and differentiation. PDL cells seeded on bone grafts pre-coated with Osteogain demonstrated significant increases in genes transcribed during bone mineralization, bone metabolism, cell growth and differentiation, extracellular matrix molecules, transcription factors and cell adhesion molecules. Lastly, we demonstrate that the application of Osteogain mixing with bone grafting significantly increases new bone formation in a rat femur defect model.
Conclusions: The development of a new carrier system for EMD specifically for bone graft mixing demonstrates more ideal physical-chemical properties suitable for future clinical use.